4Q 2017 Results and preliminary annual report

Moss, 27 February 2018

Gentian Diagnostics AS announces its results for the 4th quarter and 2017 preliminary annual results. The highlights include:

11% growth in sales revenue compared to 4Q16, 14 % y/y despite loss of our largest distributor
Increase in sales of fCAL turbo continues
Favorable development for Cystatin C in China

Please find the report enclosed.

The report will also be made available on www.gentian.com.

For further information, please contact:

Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

MeldingsID: 445248

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

Melding etter verdipapirhandelloven § 4-2 Oslo, 13 mai 2026 Vatne Capital AS, kontrollert av Runar Vatne, har..

Moss, 13 May 2026 Reference is made to the stock exchange release regarding Vatne Capital’s notification of..